Figure (Figure002)
This text provides information about a clinical trial comparing pazopanib to a placebo in terms of progression-free survival. The results show that patients on pazopanib had a median progression-free survival of 4.6 months compared to 1.6 months for those on placebo. The hazard ratio was found to be 0.35 with a 95% confidence interval of 0.26 to 0.48, indicating a significant difference between the two groups (P value < 0.001).*